Humira® (Adalimumab) is the top selling prescription drug in the world. It is FDA approved for the treatment of ten autoimmune diseases including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. Given the number of biosimilars pending Humira® patent expiration in 2023, there is a need for robust and accurate methods for Adalimumab analysis. LC-MS/MS analysis offers a solution to traditional ligand binding assay selectivity challenges. MSIA™ is a precise and accurate immunocapture method that can be fully automated for fast sample preparation.